ClinicalTrials.gg
CompletedNCT02297438Updated Nov 5, 2026Results posted

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

A Phase 3 interventional study of Palbociclib and Letrozole in Breast Neoplasms, sponsored by Pfizer. Completed at 54 sites in 5 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
23rd of 111
340 · median 100
Started
2015
with 12 others
Phase 3
20 of 111
4 open now
Registered
18th of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 23rd largest by enrollment, is one of 13 that started in 2015, is one of 20 in phase 3, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.

03

Conditions studied

  • Breast Neoplasms

Keywords

  • breast cancer
  • postmenopausal women
  • estrogen-receptor positive
  • HER2 negative
  • locoregionally recurrent
  • metastatic
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Asian women with locoregionally recurrent or disease not amenable to curative therapy
  • Confirmed diagnosis of ER positive breast cancer
  • No prior systemic anti-cancer therapy for advanced ER+ disease
  • women
  • as per Response Evaluation Criterion in Solid Tumors [] or bone-only disease
  • [ECOG] 0-1
  • Adequate organ and marrow function
  • Patient must agree to provide tumor tissue

Exclusion criteria

Exclusion Criteria:

  • Confirmed diagnosis of positive disease
  • Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
  • Known uncontrolled or symptomatic
  • Prior or adjuvant treatment with a non steroidal aromatase inhibitor (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment
  • Prior treatment with any CDK 4/6 inhibitor
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    Palbociclib + Letrozole

    Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)

    Drug: Palbociclib · Drug: Letrozole

  • Active comparator
    Placebo + Letrozole

    Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).

    Drug: Placebo · Drug: Letrozole

Interventions

  • Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

    Also known as: PD-0332991

  • Letrozole, 2.5mg, orally once daily (continuously)

  • DrugPlacebo

    Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • Letrozole, 2.5mg, orally once daily (continuously)

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date

    PFS was based on Kaplan-Meier estimates. PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. In this outcome measure, PFS was based on investigator's assessment.

    Time frame: Randomization up to 65 months

Secondary outcomes

  1. Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

    PFS was based on Kaplan-Meier estimates. PFS was defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause in the absence of documented progressive disease, whichever occurs first. In this outcome measure, PFS was based on BICR.

    Time frame: Randomization up to 65 months

  2. Percentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date

    OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.

    Time frame: Randomization up to 65 months

  3. Percentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

    OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.

    Time frame: Randomization up to 65 months

  4. Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

    OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.

    Time frame: Randomization up to 65 months

  5. Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

    OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.

    Time frame: Randomization up to 65 months

  6. Duration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date

    DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on investigator assessment.

    Time frame: Randomization up to 65 months

  7. Duration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date

    DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on BICR.

    Time frame: Randomization up to 65 months

  8. Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date

    DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.

    Time frame: Randomization up to 65 months

  9. Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

    DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.

    Time frame: Randomization up to 65 months

  10. Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

    DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.

    Time frame: Randomization up to 65 months

  11. Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

    DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.

    Time frame: Randomization up to 65 months

  12. Overall Survival (OS): Up to Primary Completion Date

    OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.

    Time frame: Randomization up to 65 months

  13. 1-Year, 2-Year and 3-Year Survival Probability: Up to Primary Completion Date

    OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. The 1-year survival probability was estimated using the Kaplan-Meier method and a 2-sided 95% confidence interval (CI) for the log \[-log(1 year survival probability)\] was be calculated using a normal approximation, and then back transformed to give a CI for the 1-year survival probability itself. The 2-year, and 3-year survival probabilities were estimated similarly.

    Time frame: Randomization up to 65 months

  14. Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Primary Completion Date

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Participants were counted only once per treatment in each row.

    Time frame: Randomization up to 65 months

  15. Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Primary Completion Date

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.

    Time frame: Randomization up to 65 months

  16. Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Primary Completion Date

    The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following hematology parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.

    Time frame: Randomization up to 65 months

  17. Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events(CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Primary Completion Date

    The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

    Time frame: Randomization up to 65 months

  18. Trough Plasma Concentration of Palbociclib

    Summary of palbociclib trough concentrations.

    Time frame: Pre-dose on Day 14 of Cycle 1 and Cycle 2

  19. Model Estimated Mean Changes From Baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) Total Score: Up to Primary Completion Date

    The Functional Assessment of Cancer Therapy (FACT) is a modular approach to assess participant health related quality of life using a "core" set of questions (FACT-G) as well as a cancer site specific module. The FACT-G was a 27-item compilation of general questions divided into 4 domains: Physical Well Being, Social/Family Well Being, Emotional Well Being, and Functional Well Being. The FACT-B consists of the FACT-G (27 items) and a breast specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a 5-level scale ranging from 0=Not at all to 4=Very much. FACT-B total score = FACT-G + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-148, with 0 being the worst possible score and 148 the best. A positive change of the total score indicated improvement from baseline and a negative change indicated deterioration.

    Time frame: Baseline up to Cycle 65 Day 1

  20. Model Estimated Mean Change From Baseline in Euro Quality of Life 5-Dimension Scale (EQ-5D) Index Scores: Up to Primary Completion Date

    The EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/depression); a participant was asked to rate each state on a 3 level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment.

    Time frame: Baseline up to Cycle 65 Day 1

  21. Model Estimated Mean Change From Baseline in Euro Quality of Life (EQ) Visual Analog Scale (VAS) Scores: Up to Primary Completion Date

    The EQ VAS recorded the participant's self rated questionnaire to assess generic health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Published weights were available that allow for the creation of a single summary score.

    Time frame: Baseline up to Cycle 65 Day 1

  22. Median Baseline Percent (%) Positive Cells for Ki67

    Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of Ki67 associated with sensitivity and/or resistance to Palbociclib.

    Time frame: Baseline

  23. Number of Participants With Detection in Estrogen Receptor (ER)

    Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of ER associated with sensitivity and/or resistance to Palbociclib.

    Time frame: Baseline

Other outcomes

  1. Overall Survival: Up to Secondary Completion Date

    OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.

    Time frame: Randomization up to 65 months

  2. Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Secondary Completion Date

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)

  3. Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Secondary Completion Date

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.

    Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)

  4. Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Secondary Completion Date

    The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift data were provided to examine the distribution of laboratory toxicities. The following hematology parameters met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.

    Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)

  5. Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Secondary Completion Date

    The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: ALT, alkaline phosphatase, AST, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

    Time frame: Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)

07

Results

Posted Nov 18, 2021

Participant flow

Participant flow — Overall Study
MilestonePalbociclib + LetrozolePlacebo + Letrozole
Started169171
Completed00
Not completed169171
Withdrew: Death102126
Withdrew: Lost to follow-up1411
Withdrew: Withdrawal by subject106
Withdrew: Other3423
Withdrew: Participant refused further follow-up95

Outcome measures

PrimaryProgression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date

PFS was based on Kaplan-Meier estimates. PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. In this outcome measure, PFS was based on investigator's assessment.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date21.5 (16.6 to 24.9)13.9 (13.7 to 16.6)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Log Rank · p = 0.0012 (1-sided p-value from the adjusted log-rank test.) · Hazard ratio (hr): 0.677 · 95% CI 0.529 to 0.867Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Letrozole.
SecondaryProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

PFS was based on Kaplan-Meier estimates. PFS was defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause in the absence of documented progressive disease, whichever occurs first. In this outcome measure, PFS was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date21.6 (16.6 to 30.4)16.4 (13.8 to 22.2)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Log Rank · p = 0.14778 (1-sided p-value from the log-rank test.) · Hazard ratio (hr): 0.861 · 95% CI 0.651 to 1.139Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of Palbociclib + Letrozole.
SecondaryPercentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date

OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment: Up to Primary Completion Date37.3 (30.0 to 45.0)31.6 (24.7 to 39.1)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.154 (1-sided p-value was from exact test.) · Odds ratio (or): 1.301 · 95% CI 0.805 to 2.100An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Objective Response (OR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date43.4 (35.2 to 51.9)38.0 (30.0 to 46.5)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.206 (1-sided p-value was from exact test.) · Odds ratio (or): 1.255 · 95% CI 0.762 to 2.066An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date40.2 (32.8 to 48.0)33.9 (26.9 to 41.5)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.135 (1-sided p-value was from exact test.) · Odds ratio (or): 1.315 · 95% CI 0.825 to 2.095An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Objective Response (OR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date52.3 (43.3 to 61.2)43.5 (34.9 to 52.4)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.117 (1-sided p-value was from exact test.) · Odds ratio (or): 1.392 · 95% CI 0.825 to 2.346An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryDuration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date

DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on investigator assessment.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Duration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Duration of Response (DOR) Based on Investigator Assessment (Participants With Objective Disease Response): Up to Primary Completion Date22.4 (19.4 to 56.2)19.4 (13.8 to 24.4)
SecondaryDuration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date

DOR was defined as the time from the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Duration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Duration of Response (DOR) Based on Blinded Independent Central Review (BICR) (Participants With Objective Disease Response): Up to Primary Completion Date30.3 (19.4 to NA)24.9 (11.5 to 36.1)
SecondaryPercentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date

DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment: Up to Primary Completion Date79.3 (72.4 to 85.1)80.1 (73.3 to 85.8)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.471 (1-sided p-value was from exact test.) · Odds ratio (or): 0.945 · 95% CI 0.533 to 1.673An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Investigator Assessment (Participants With Measurable Disease at Baseline): Up to Primary Completion Date77.9 (70.3 to 84.4)79.6 (72.0 to 85.9)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.383 (1-sided p-value was from exact test.) · Odds ratio (or): 0.878 · 95% CI 0.474 to 1.621An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date

DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR): Up to Primary Completion Date76.9 (69.8 to 83.0)73.1 (65.8 to 79.6)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.248 (1-sided p-value was from exact test.) · Odds ratio (or): 1.227 · 95% CI 0.725 to 2.082An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryPercentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date

DC/CBR was defined as CR, PR, or stable disease (SD) \>=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
Percentage of Participants With Disease Control/Clinical Benefit Response (DC/CBR) Based on Blinded Independent Central Review (BICR) (Participants With Measurable Disease at Baseline): Up to Primary Completion Date78.1 (70.0 to 84.9)71.8 (63.2 to 79.3)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Fisher Exact · p = 0.189 (1-sided p-value was from exact test.) · Odds ratio (or): 1.349 · 95% CI 0.731 to 2.509An Odds Ratio \>1 means better response in favor of Palbociclib + Letrozole group.
SecondaryOverall Survival (OS): Up to Primary Completion Date

OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Overall Survival (OS): Up to Primary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Overall Survival (OS): Up to Primary Completion Date51.7 (43.0 to NA)51.5 (41.0 to NA)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Log Rank · p = 0.36502 (1-sided p-value was from exact test.) · Hazard ratio (hr): 0.947 · 95% CI 0.698 to 1.286Assuming Cox proportional hazards, hazard ratio less than 1 indicates reduction in hazard rate in favor of Palbociclib + Letrozole.
Other pre-specifiedOverall Survival: Up to Secondary Completion Date

OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods.

Time frame:
Randomization up to 65 months
Reported as:
Median · Months
Overall Survival: Up to Secondary Completion Date
MonthsPalbociclib + LetrozolePlacebo + Letrozole
Overall Survival: Up to Secondary Completion Date50.3 (43.0 to 63.5)49.7 (41.0 to 58.1)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Log Rank · p = 0.06764 (1-sided p-value was from log rank test.) · Hazard ratio (hr): 0.819 · 95% CI 0.631 to 1.064Assuming Cox proportional hazards, hazard ratio less than 1 indicates reduction in hazard rate in favor of Palbociclib + Letrozole.
Secondary1-Year, 2-Year and 3-Year Survival Probability: Up to Primary Completion Date

OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. The 1-year survival probability was estimated using the Kaplan-Meier method and a 2-sided 95% confidence interval (CI) for the log \[-log(1 year survival probability)\] was be calculated using a normal approximation, and then back transformed to give a CI for the 1-year survival probability itself. The 2-year, and 3-year survival probabilities were estimated similarly.

Time frame:
Randomization up to 65 months
Reported as:
Number · Percentage of participants
1-Year, 2-Year and 3-Year Survival Probability: Up to Primary Completion Date
Percentage of participantsPalbociclib + LetrozolePlacebo + Letrozole
1-year survival probability92.8 (87.6 to 95.8)90.5 (85.0 to 94.1)
2-year survival probability80.3 (73.3 to 85.6)78.0 (71.0 to 83.6)
3-year survival probability67.1 (59.1 to 73.8)60.6 (52.7 to 67.5)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Primary Completion Date

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Participants were counted only once per treatment in each row.

Time frame:
Randomization up to 65 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Primary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Participants with AEs168155
Participants with SAEs2616
Participants with Grade 3 or 4 AEs15238
Participants with Grade 5 AEs42
Participants discontinued study due to AEs135
Participants discontinued Palbociclib/Placebo or Letrozole due to AEs114
Participants discontinued Palbociclib/Placebo due to AEs114
Participants discontinued Letrozole due to AEs103
Participants temporarily discontinued Palbociclib/Placebo due to AEs13617
Participants temporarily discontinued Letrozole due to AEs119
Participants with dose reduction of Palbociclib/Placebo due to AEs162
Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs382
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Secondary Completion Date

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities): Up to Secondary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Participants with AEs168155
Participants with SAEs3419
Participants with Grade 3 or 4 AEs15240
Participants with Grade 5 AEs43
Participants discontinued study due to AEs146
Participants discontinued Palbociclib/Placebo or Letrozole due to AEs124
Participants temporarily discontinued Palbociclib/Placebo due to AEs13721
Participants temporarily discontinued Letrozole due to AEs1814
Participants with dose reduction of Palbociclib/Placebo due to AEs162
Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs382
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Primary Completion Date

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.

Time frame:
Randomization up to 65 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Primary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Participants with AEs167123
Participants with SAEs83
Participants with Grade 3 or 4 AEs14918
Participants with Grade 5 AEs10
Participants discontinued study due to AEs62
Participants discontinued Palbociclib/Placebo or Letrozole due to AEs52
Participants discontinued due to AEs related to Palbociclib/Placebo52
Participants discontinued due to AEs related to Letrozole10
Participants temporarily discontinued Palbociclib/Placebo due to AEs13211
Participants temporarily discontinued Letrozole due to AEs75
Participants with dose reduction of Palbociclib/Placebo due to AEs152
Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs372
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Secondary Completion Date

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row.

Time frame:
Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related): Up to Secondary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Participants with AEs167123
Participants with SAEs125
Participants with Grade 3 or 4 AEs14920
Participants with Grade 5 AEs11
Participants discontinued study due to AEs73
Participants discontinued Palbociclib/Placebo or Letrozole due to AEs62
Participants temporarily discontinued Palbociclib/Placebo due to AEs13312
Participants temporarily discontinued Letrozole due to AEs117
Participants with dose reduction of Palbociclib/Placebo due to AEs152
Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs372
SecondaryNumber of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Primary Completion Date

The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following hematology parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.

Time frame:
Randomization up to 65 months
Reported as:
Count of participants · Participants
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Primary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Neutrophils (absolute)1432
White blood cells771
Platelets131
Anemia103
Hemoglobin increased30
Other pre-specifiedNumber of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Secondary Completion Date

The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift data were provided to examine the distribution of laboratory toxicities. The following hematology parameters met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased.

Time frame:
Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Reported as:
Count of participants · Participants
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Hematology: Up to Secondary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Neutrophils (Absolute)1432
White blood cells811
Platelets171
Anemia133
Haemoglobin increased30
SecondaryNumber of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events(CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Primary Completion Date

The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

Time frame:
Randomization up to 65 months
Reported as:
Count of participants · Participants
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events(CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Primary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
ALT91
Alkaline phosphatase02
AST96
Bilirubin (total)22
Creatinine10
Hypercalcemia12
Hyperglycemia11
Hyperkalemia10
Hypermagnesemia108
Hypernatremia21
Hypoalbuminemia00
Hypocalcemia11
Hypoglycemia01
Hypokalemia36
Hypomagnesemia31
Hyponatremia112
Other pre-specifiedNumber of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Secondary Completion Date

The laboratory results were graded according to the NCI CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: ALT, alkaline phosphatase, AST, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

Time frame:
Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization)
Reported as:
Count of participants · Participants
Number of Participants With Postbaseline Laboratory Abnormalities of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 (Participants With Baseline Laboratory Abnormalities of CTCAE Grade <=2) - Chemistry: Up to Secondary Completion Date
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
ALT101
Alkaline phosphatase02
AST96
Bilirubin Total32
Creatinine10
Hypercalcemia12
Hyperglycemia21
Hyperkalemia00
Hypermagnesemia99
Hypernatremia21
Hypoalbuminemia00
Hypocalcemia11
Hypoglycemia01
Hypokalemia36
Hypomagnesemia41
Hyponatremia102
SecondaryTrough Plasma Concentration of Palbociclib

Summary of palbociclib trough concentrations.

Time frame:
Pre-dose on Day 14 of Cycle 1 and Cycle 2
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentration of Palbociclib
ng/mLPalbociclib + Letrozole
Cycle 181.1 ± 29
Cycle 277.4 ± 43
Average trough concentration80.2 ± 36
SecondaryModel Estimated Mean Changes From Baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) Total Score: Up to Primary Completion Date

The Functional Assessment of Cancer Therapy (FACT) is a modular approach to assess participant health related quality of life using a "core" set of questions (FACT-G) as well as a cancer site specific module. The FACT-G was a 27-item compilation of general questions divided into 4 domains: Physical Well Being, Social/Family Well Being, Emotional Well Being, and Functional Well Being. The FACT-B consists of the FACT-G (27 items) and a breast specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a 5-level scale ranging from 0=Not at all to 4=Very much. FACT-B total score = FACT-G + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-148, with 0 being the worst possible score and 148 the best. A positive change of the total score indicated improvement from baseline and a negative change indicated deterioration.

Time frame:
Baseline up to Cycle 65 Day 1
Reported as:
Mean · Units on a scale
Model Estimated Mean Changes From Baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) Total Score: Up to Primary Completion Date
Units on a scalePalbociclib + LetrozolePlacebo + Letrozole
Cycle 2 Day 11.618 (-0.15 to 3.39)1.021 (-0.74 to 2.78)
Cycle 3 Day 11.441 (-0.32 to 3.20)0.850 (-0.90 to 2.60)
Cycle 5 Day 11.087 (-0.69 to 2.86)0.510 (-1.25 to 2.27)
Cycle 7 Day 10.732 (-1.07 to 2.53)0.169 (-1.62 to 1.96)
Cycle 9 Day 10.378 (-1.48 to 2.23)-0.171 (-2.02 to 1.68)
Cycle 11 Day 10.024 (-1.90 to 1.95)-0.512 (-2.44 to 1.41)
Cycle 13 Day 1-0.331 (-2.34 to 1.68)-0.852 (-2.88 to 1.17)
Cycle 15 Day 1-0.685 (-2.80 to 1.43)-1.193 (-3.33 to 0.95)
Cycle 17 Day 1-1.039 (-3.27 to 1.19)-1.534 (-3.80 to 0.74)
Cycle 19 Day 1-1.393 (-3.75 to 0.96)-1.874 (-4.29 to 0.54)
Cycle 21 Day 1-1.748 (-4.24 to 0.75)-2.215 (-4.78 to 0.35)
Cycle 23 Day 1-2.102 (-4.74 to 0.54)-2.555 (-5.28 to 0.17)
Cycle 25 Day 1-2.456 (-5.24 to 0.33)-2.896 (-5.79 to 0.00)
Cycle 27 Day 1-2.810 (-5.76 to 0.13)-3.326 (-6.31 to -0.16)
Cycle 29 Day 1-3.165 (-6.27 to -0.06)-3.577 (-6.83 to -0.33)
Cycle 31 Day 1-3.519 (-6.79 to -0.25)-3.918 (-7.35 to -0.48)
Cycle 33 Day 1-3.873 (-7.31 to -0.43)-4.258 (-7.88 to -0.64)
Cycle 35 Day 1-4.227 (-7.84 to -0.62)-4.599 (-8.41 to -0.79)
Cycle 37 Day 1-4.582 (-8.37 to -0.80)-4.939 (-8.95 to -0.93)
Cycle 39 Day 1-4.936 (-8.90 to -0.97)-5.280 (-9.48 to -1.08)
Cycle 41 Day 1-5.290 (-9.43 to -1.15)-5.620 (-10.02 to -1.22)
Cycle 43 Day 1-5.644 (-9.97 to -1.32)-5.961 (-10.56 to -1.36)
Cycle 45 Day 1-5.999 (-10.50 to -1.50)-6.301 (-11.10 to -1.50)
Cycle 47 Day 1-6.353 (-11.04 to -1.67)-6.642 (-11.64 to -1.64)
Cycle 49 Day 1-6.707 (-11.58 to -1.84)-6.983 (-12.18 to -1.78)
Cycle 51 Day 1-7.061 (-12.12 to -2.00)-7.323 (-12.73 to -1.92)
Cycle 53 Day 1-7.416 (-12.66 to -2.17)-7.664 (-13.27 to -2.05)
Cycle 55 Day 1-7.770 (-13.20 to -2.34)-8.004 (-13.82 to -2.19)
Cycle 57 Day 1-8.124 (-13.74 to -2.51)-8.345 (-14.37 to -2.32)
Cycle 59 Day 1-8.478 (-14.29 to -2.67)-8.685 (-14.91 to -2.46)
Cycle 61 Day 1-8.833 (-14.83 to -2.84)-9.026 (-15.46 to -2.59)
Cycle 63 Day 1-9.187 (-15.37 to -3.00)-9.367 (-16.01 to -2.72)
Cycle 65 Day 1-9.541 (-15.92 to -3.16)-9.707 (-16.56 to -2.86)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Mixed effects model · p = 0.7862 · Mean: 0.476 · 95% CI -2.97 to 3.92A positive change indicates improvement from baseline and a negative change indicates deterioration.
SecondaryModel Estimated Mean Change From Baseline in Euro Quality of Life 5-Dimension Scale (EQ-5D) Index Scores: Up to Primary Completion Date

The EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/depression); a participant was asked to rate each state on a 3 level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment.

Time frame:
Baseline up to Cycle 65 Day 1
Reported as:
Mean · Units on a scale
Model Estimated Mean Change From Baseline in Euro Quality of Life 5-Dimension Scale (EQ-5D) Index Scores: Up to Primary Completion Date
Units on a scalePalbociclib + LetrozolePlacebo + Letrozole
Cycle 2 Day 10.013 (-0.01 to 0.03)0.014 (-0.01 to 0.03)
Cycle 3 Day 10.012 (-0.01 to 0.03)0.011 (-0.01 to 0.03)
Cycle 5 Day 10.010 (-0.01 to 0.03)0.005 (-0.01 to 0.03)
Cycle 7 Day 10.008 (-0.01 to 0.03)0.000 (-0.02 to 0.02)
Cycle 9 Day 10.006 (-0.02 to 0.03)-0.006 (-0.03 to 0.02)
Cycle 11 Day 10.004 (-0.02 to 0.03)-0.012 (-0.04 to 0.01)
Cycle 13 Day 10.02 (-0.02 to 0.03)-0.017 (-0.04 to 0.01)
Cycle 15 Day 10.000 (-0.03 to 0.03)-0.023 (-0.05 to 0.01)
Cycle 17 Day 1-0.002 (-0.03 to 0.03)-0.029 (-0.06 to 0.00)
Cycle 19 Day 1-0.004 (-0.04 to 0.03)-0.034 (-0.07 to 0.00)
Cycle 21 Day 1-0.006 (-0.04 to 0.03)-0.040 (-0.08 to 0.00)
Cycle 23 Day 1-0.008 (-0.05 to 0.03)-0.045 (-0.08 to -0.01)
Cycle 25 Day 1-0.010 (-0.05 to 0.03)-0.051 (-0.09 to -0.01)
Cycle 27 Day 1-0.012 (-0.05 to 0.03)-0.057 (-0.10 to -0.01)
Cycle 29 Day 1-0.014 (-0.06 to 0.03)-0.062 (-0.11 to -0.02)
Cycle 31 Day 1-0.016 (-0.06 to 0.03)-0.068 (-0.12 to -0.02)
Cycle 33 Day 1-0.018 (-0.07 to 0.03)-0.074 (-0.13 to -0.02)
Cycle 35 Day 1-0.020 (-0.07 to 0.03)-0.079 (-0.13 to -0.02)
Cycle 37 Day 1-0.022 (-0.08 to 0.03)-0.085 (-0.14 to -0.03)
Cycle 39 Day 1-0.024 (-0.08 to 0.03)-0.090 (-0.15 to -0.03)
Cycle 41 Day 1-0.027 (-0.09 to 0.03)-0.096 (-0.16 to -0.03)
Cycle 43 Day 1-0.029 (-0.09 to 0.04)-0.102 (-0.17 to -0.03)
Cycle 45 Day 1-0.031 (-0.10 to 0.04)-0.107 (-0.18 to -0.04)
Cycle 47 Day 1-0.033 (-0.10 to 0.04)-0.113 (-0.19 to -0.04)
Cycle 49 Day 1-0.035 (-0.11 to 0.04)-0.119 (-0.20 to -0.04)
Cycle 51 Day 1-0.037 (-0.11 to 0.04)-0.124 (-0.20 to -0.04)
Cycle 53 Day 1-0.039 (-0.12 to 0.04)-0.130 (-0.21 to -0.05)
Cycle 55 Day 1-0.041 (-0.12 to 0.04)-0.136 (-0.22 to -0.05)
Cycle 57 Day 1-0.043 (-0.13 to 0.04)-0.141 (-0.23 to -0.05)
Cycle 59 Day 1-0.045 (-0.13 to 0.04)-0.147 (-0.24 to -0.05)
Cycle 61 Day 1-0.047 (-0.14 to 0.04)-0.152 (-0.25 to -0.06)
Cycle 63 Day 1-0.049 (-0.14 to 0.04)-0.158 (-0.26 to -0.06)
Cycle 65 Day 1-0.051 (-0.15 to 0.04)-0.164 (-0.27 to -0.06)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Mixed effects model · p = 0.1914 · Mean: 0.031 · 95% CI -0.02 to 0.08A positive change indicates improvement from baseline and a negative change indicates deterioration.
SecondaryModel Estimated Mean Change From Baseline in Euro Quality of Life (EQ) Visual Analog Scale (VAS) Scores: Up to Primary Completion Date

The EQ VAS recorded the participant's self rated questionnaire to assess generic health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Published weights were available that allow for the creation of a single summary score.

Time frame:
Baseline up to Cycle 65 Day 1
Reported as:
Mean · Units on a scale
Model Estimated Mean Change From Baseline in Euro Quality of Life (EQ) Visual Analog Scale (VAS) Scores: Up to Primary Completion Date
Units on a scalePalbociclib + LetrozolePlacebo + Letrozole
Cycle 2 Day 13.047 (1.53 to 4.57)1.861 (0.35 to 3.37)
Cycle 3 Day 13.125 (1.62 to 4.63)1.815 (0.32 to 3.31)
Cycle 5 Day 13.279 (1.79 to 4.77)1.724 (0.24 to 3.21)
Cycle 7 Day 13.434 (1.94 to 4.92)1.634 (0.16 to 3.11)
Cycle 9 Day 13.589 (2.09 to 5.09)1.543 (0.05 to 3.03)
Cycle 11 Day 13.743 (2.22 to 5.26)1.452 (-0.06 to 2.97)
Cycle 13 Day 13.898 (2.35 to 5.45)1.361 (-0.19 to 2.92)
Cycle 15 Day 14.052 (2.46 to 5.65)1.271 (-0.34 to 2.88)
Cycle 17 Day 14.207 (2.56 to 5.85)1.180 (-0.49 to 2.85)
Cycle 19 Day 14.362 (2.65 to 6.07)1.089 (-0.65 to 2.83)
Cycle 21 Day 14.516 (2.74 to 6.29)0.998 (-0.83 to 2.82)
Cycle 23 Day 14.671 (2.82 to 6.52)0.908 (-1.01 to 2.82)
Cycle 25 Day 14.826 (2.89 to 6.76)0.817 (-1.20 to 2.83)
Cycle 27 Day 14.980 (2.96 to 7.00)0.726 (-1.39 to 2.84)
Cycle 29 Day 15.135 (3.02 to 7.25)0.635 (-1.59 to 2.86)
Cycle 31 Day 15.289 (3.08 to 7.50)0.545 (-1.79 to 2.88)
Cycle 33 Day 15.444 (3.13 to 7.76)0.454 (-1.99 to 2.90)
Cycle 35 Day 15.599 (3.18 to 8.02)0.363 (-2.20 to 2.93)
Cycle 37 Day 15.753 (3.23 to 8.28)0.272 (-2.42 to 2.96)
Cycle 39 Day 15.908 (3.28 to 8.54)0.182 (-2.63 to 2.99)
Cycle 41 Day 16.063 (3.32 to 8.81)0.091 (-2.85 to 3.03)
Cycle 43 Day 16.217 (3.36 to 9.07)0.000 (-3.06 to 3.06)
Cycle 45 Day 16.372 (3.40 to 9.34)-0.091 (-3.28 to 3.10)
Cycle 47 Day 16.526 (3.44 to 9.61)-0.181 (-3.51 to 3.14)
Cycle 49 Day 16.681 (3.48 to 9.89)-0.272 (-3.73 to 3.18)
Cycle 51 Day 16.836 (3.51 to 10.16)-0.363 (-3.95 to 3.23)
Cycle 53 Day 16.990 (3.55 to 10.43)-0.454 (-4.18 to 3.27)
Cycle 55 Day 17.145 (3.58 to 10.71)-0.544 (-4.40 to 3.31)
Cycle 57 Day 17.300 (3.61 to 10.99)-0.635 (-4.63 to 3.36)
Cycle 59 Day 17.454 (3.64 to 11.26)-0.726 (-4.86 to 3.41)
Cycle 61 Day 17.609 (3.68 to 11.54)-0.817 (-5.08 to 3.45)
Cycle 63 Day 17.763 (3.71 to 11.82)-0.907 (-5.31 to 3.50)
Cycle 65 Day 17.918 (3.74 to 12.10)-0.998 (-5.54 to 3.55)
Statistical analysis
  • Palbociclib + Letrozole vs Placebo + Letrozole · Mixed effects model · p = 0.0078 · Mean: 3.358 · 95% CI 0.88 to 5.83A positive change indicates improvement from baseline and a negative change indicates deterioration.
SecondaryMedian Baseline Percent (%) Positive Cells for Ki67

Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of Ki67 associated with sensitivity and/or resistance to Palbociclib.

Time frame:
Baseline
Reported as:
Median · Percentage of Ki67 positive cells
Median Baseline Percent (%) Positive Cells for Ki67
Percentage of Ki67 positive cellsPalbociclib + LetrozolePlacebo + Letrozole
Median Baseline Percent (%) Positive Cells for Ki6730.0 (0 to 95)27.5 (0 to 95)
SecondaryNumber of Participants With Detection in Estrogen Receptor (ER)

Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of ER associated with sensitivity and/or resistance to Palbociclib.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Detection in Estrogen Receptor (ER)
ParticipantsPalbociclib + LetrozolePlacebo + Letrozole
Positive152162
Negative21
Unknown148

Adverse events

Collected over Up to 28 days after last dose of study drug or start of new treatment (data collection maximum up to approximately 119 months after randomization). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib + Letrozole102/168 (60.7%)34/168 (20.2%)168/168 (100%)
Placebo + Letrozole126/171 (73.7%)19/171 (11.1%)143/171 (83.6%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPalbociclib + LetrozolePlacebo + Letrozole
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1680/171
CataractEye disorders2/1680/171
PyrexiaGeneral disorders2/1680/171
PneumoniaInfections and infestations2/1682/171
Urinary tract infectionInfections and infestations2/1682/171
Ankle fractureInjury, poisoning and procedural complications2/1680/171
Platelet count decreasedInvestigations2/1681/171
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1680/171
HypercalcaemiaMetabolism and nutrition disorders0/1682/171
AnaemiaBlood and lymphatic system disorders1/1680/171
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPalbociclib + LetrozolePlacebo + Letrozole
Neutrophil count decreasedInvestigations112/16819/171
White blood cell count decreasedInvestigations108/16817/171
NeutropeniaBlood and lymphatic system disorders75/16812/171
Platelet count decreasedInvestigations73/1687/171
AnaemiaBlood and lymphatic system disorders69/16816/171
Aspartate aminotransferase increasedInvestigations61/16849/171
Alanine aminotransferase increasedInvestigations60/16858/171
LeukopeniaBlood and lymphatic system disorders51/1689/171
CoughRespiratory, thoracic and mediastinal disorders28/16822/171
Electrocardiogram QT prolongedInvestigations27/16816/171

Baseline characteristics

Age, Continuous
Age, Continuous(years)Palbociclib + LetrozolePlacebo + LetrozoleTotal
Mean53.8 ± 8.553.7 ± 9.153.8 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib + LetrozolePlacebo + LetrozoleTotal
Female169171340
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Palbociclib + LetrozolePlacebo + LetrozoleTotal
Asian169171340
08

Study locations

54 sites
  • The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
    Bengbu, Anhui 233004, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Fujian Medical University Union Hospital/Medical Oncology Department
    Fuzhou, Fujian 350001, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Zhongshan Ophthalmic Center,Sun Yat-Sen University
    Guangzhou, Guangdong 510060, China
  • Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510120, China
  • Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Cancer Hospital/Oncology Department
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Hunan Provincial Tumor Hospital/Breast Internal Medicine Department
    Changsha, Hunan 410013, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Jilin Provincial Cancer Hospital
    Changchun, Jilin 130103, China
  • The First Hospital of China Medical University/Oncology Department
    Shenyang, Liaoning 110001, China
  • Liaoning Province Cancer Hospital
    Shenyang, Liaoning 110042, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Cancer Hospital/Breast cancer department
    Tianjin, Tianjin Municipality 300060, China
  • The Tumor Hospital of Yunnan Province
    Kunming, Yunnan 650118, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, 100021, China
  • 307 Hospital of PLA
    Beijing, 100071, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Peking University Third Hospital/Department of Oncology
    Beijing, 100191, China
  • Chinese PLA General Hospital/Oncology
    Beijing, 100853, China
  • Oncology Department, the Second Affiliated Hospital of Third Military Medical University, PLA
    Chongqing, 400037, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Department of Clinical Oncology
    Hong Kong, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Raffles Cancer Centre
    Singapore, 188770, Singapore
  • Parkway Cancer Centre
    Singapore, 258500, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308442, Singapore
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital / Internal Medicine
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • Taipei Medical University Hospital/ Department of Surgery
    Taipei, 110, Taiwan
  • Taipei Veterans General Hospital/Surgery Department
    Taipei, 11217, Taiwan
  • Koo Foundation, Sun Yat-Sen Cancer Center
    Taipei, 11259, Taiwan
  • Taipei Municipal Wanfang Hospital (Managed by Taipei Medical University )
    Taipei, 116, Taiwan
  • King Chulalongkorn Memorial Hospital
    Pathumwan, Bangkok 10330, Thailand
  • Chula Clinical Research Center (Chula CRC)
    Patumwan, Bangkok 10330, Thailand
  • Department of Medicine, Faculty of Medicine, Naresuan University
    Muang, Changwat Phitsanulok 65000, Thailand
  • Division of Therapeutic Radiology and Oncology, Department of Radiology
    Muang, Chiang Mai 50200, Thailand
  • Ramathibodi Hospital, Mahidol University
    Bangkok, Ratchathevi 10400, Thailand
  • Oncology Unit, Department of Internal Medicine, Phramongkutklao Hospital
    Bangkok, 10400, Thailand
  • Division of Medical Oncology, Department of Medicine,
    Bangkok, 10700, Thailand
09

References and documents

Publications

  • Xu B, Hu X, Li W, Sun T, Shen K, Huang C, Sriuranpong V, Ngan RK, Chia YH, Reisman A, Zhao H, Shen J, Broughton E. Patient-reported quality of life in Asian patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial. Chin Med J (Engl). 2024 Dec 19. doi: 10.1097/CM9.0000000000003122. Online ahead of print. PubMed 39694573 ↗
  • Xu B, Hu X, Li W, Sun T, Shen K, Wang S, Cheng Y, Zhang Q, Cui S, Tong Z, Geng C, Song E, Huang CS, Sriuranpong V, Ngan RKC, Chia YH, Wang X, Zhao H. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022 Nov;175:236-245. doi: 10.1016/j.ejca.2022.08.012. Epub 2022 Sep 22. PubMed 36155117 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Aug 2020, 65 months.

Results were first posted in Nov 2021, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 65 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2014
First posted
Nov 21, 2014
StartActual
Mar 23, 2015
Primary completionActual
Aug 31, 2020
CompletionActual
Feb 24, 2025
Results first posted
Nov 18, 2021
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02297438
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 21, 2014
Start date
Mar 23, 2015
Primary completion
Aug 31, 2020
Completion
Feb 24, 2025
Results posted
Nov 18, 2021
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion